07-01-2016 дата публикации
Номер: US20160002321A1
The characterization and isolation of F20G75, F20G76 and F20G77, anti-PA monoclonal antibodies which also have neutralizing activities is described. The monoclonal antibodies may be used as a pharmaceutical composition for treating individuals suspected of or at risk of or having a infection. The monoclonal antibodies bind to a specific region comprising amino acids 311-316 of PA, ASFFDI or a larger fragment comprising amino acids 301-330 of PA, SEVHGNAEVHASFFDIGSSVSAGFSNSNSS. Vaccines comprising these peptides may be used to immunize individuals against infection. 1Bacillus anthracis. An anti-antibody comprising an amino acid sequence as set forth in any one of SEQ ID No. 10 , 12 , 14 , 16 , 18 or 20.2. The antibody according to wherein the antibody is a chimeric antibody.3Bacillus anthracis. A neutralizing monoclonal antibody selected from the group consisting of F20G75 claim 1 , F20G76 and F20G77. The instant application is a divisional application of U.S. Ser. No. 12/301,034, filed May 1, 2009 which is a 371 of PCT Application CA07/00872, filed May 17, 2007, now abandoned, which claims the benefit of US Provisional patent application, filed May 17, 2006 number 60/800,831, entitled ‘MONOCLONAL ANTIBODIES TO ANTHRAX PROTECTIVE ANTIGEN’, now abandoned, the contents of which are incorporated herein by reference.The invention relates to vaccines for infections.Anthrax is a well-known infectious disease caused by a Gram-positive bacterium, . There are three types of anthrax infections: cutaneous, gastrointestinal and inhalation. Inhalation anthrax generally occurs after an incubation time of 1-6 days. After the incubation period, a non-specific flu-like illness ensues for 1-3 days followed by a brief intervening period of improvement. Unfortunately, rapid deterioration follows and death is universal in untreated cases.Airborne anthrax has long been concerned a major bioterror threat and it has recently been shown that anthrax can be aerosolized and transmitted by mail ...
Подробнее
